gallium-68-dotatate (netspot) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

  • Now
Dotatate gallium (Ga-68) (Ga-DOTATATE ) under the brand name NETSPOT is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. In addition, was shown, that Ga-DOTATATE can be used for detection the incidental medullary thyroid carcinoma. It binds to cells that express somatostatin receptors including malignant cells, which overexpress somatostatin subtype 2 receptors.   NCATS

  • SMILES: [68Ga+3].CC(O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN3CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC3)C(=O)N[C@@H](CC4=CC=C(O)C=C4)C(=O)N[C@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O
  • Mol. Mass: 1500.527
  • ALogP: Missing data
  • ChEMBL Molecule:
More Chemistry
  • Mechanisms of Action: Missing data
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No
(68ga-dota-3-iodo-tyr(3),thr(8))octreotide | 68ga-dota-iodo-tyr(3)-octreotate | 68ga dotatate | 68ga-dotatate | (68ga)gallium dotatate | 68ga-ha-dotatate | 68gallium-dota-tyr(3)-thr(8)-octreotate | dotatate gallium ga-68 | edotreotide gallium ga-68 | ga-68 dota0-tyr3-octreotide | ga-68 dotatoc | ga-dotatate | gallium 68 dota-octreotide | gallium 68 dotatate | gallium-68-dotatate | gallium (68ga) dota-tate | gallium (68ga) edotreotide | gallium-dota-octreotate, ga-68 | gallium dotatate ga-68 | gallium dotatate, ga-68 | gallium edotreotide ga-68 | gallium ga 68 dotatate | gallium ga 68-dotatoc | gallium ga 68-edotreotide | gallium ga-68 edotreotide | netspot


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue